

Japanese cedar pollen antigen, or both the B cell response and the T cell response of the individual to Japanese cedar pollen allergen.

96. The purified allergen or antigenic fragment of claim 94 wherein said purified allergen or said antigenic fragment is capable of modifying B-cell response of the individual to a Japanese cedar pollen allergen, T-cell response of the individual to a Japanese cedar pollen antigen, or both the B cell response and the T cell response of the individual to Japanese cedar pollen allergen.

97. The isolated protein allergen or fragment thereof of claim 67 wherein said isolated protein allergen or antigenic fragment thereof is capable of stimulating T cells specific for *Cry j I* or a fragment thereof.


98. The therapeutic composition of claim 68 wherein *Cry j I* has the sequence of amino acids 1-353 of SEQ ID NO: 1.

REMARKS

New claims 76-98 have been added to the case. Support for claims 76-98 is found throughout the specification and drawings and particularly at pages 6-11 and Figs 4a and 4b.

If the Examiner has any questions regarding this amendment or this application, the Examiner is cordially invited to telephone the undersigned attorney.

Respectfully submitted,



Darlene A. Vanstone, Reg. No. 35,729
Attorney for Applicants

May 21, 1993
ImmuLogic Pharmaceutical Corporation
610 Lincoln Street
Waltham, MA 02154
Telephone: 617-466-6000